Cogent Biosciences Raises $200 Million in Public Offering to Advance Precision Therapies

Cogent Biosciences, a biotechnology company, priced its public offering of 22,222,223 shares at $9.00 per share, totaling around $200 million. The company plans to use the proceeds for product development, regulatory activities, and commercial preparation for bezuclastinib. J.P. Morgan, Leerink Partners, and Guggenheim Securities are managing the offering. The securities are offered under an automatic shelf registration statement on Form S-3ASR. Cogent Biosciences is focused on developing precision therapies for genetically defined diseases, with bezuclastinib as its most advanced clinical program. The company is headquartered in Waltham, MA and Boulder, CO.

Read more at GlobeNewswire: Cogent Biosciences Announces Pricing of Upsized Public